©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2018; 24(20): 2152-2162
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2152
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2152
Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours
Ashley Kieran Clift, Andrea Frilling, Department of Surgery and Cancer, Imperial College London, London W12 0HS, United Kingdom
Author contributions: Both authors contributed equally to this work and approved the final version.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Correspondence to: Andrea Frilling, MD, PhD, Professor, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, United Kingdom. a.frilling@imperial.ac.uk
Telephone: +44-208-3833941 Fax: +44-203-3133963
Received: April 3, 2018
Peer-review started: April 4, 2018
First decision: April 19, 2018
Revised: May 3, 2018
Accepted: May 18, 2018
Article in press: May 18, 2018
Published online: May 28, 2018
Processing time: 54 Days and 21 Hours
Peer-review started: April 4, 2018
First decision: April 19, 2018
Revised: May 3, 2018
Accepted: May 18, 2018
Article in press: May 18, 2018
Published online: May 28, 2018
Processing time: 54 Days and 21 Hours
Core Tip
Core tip: Liver transplantation is a generally accepted option in selected patients with advanced neuroendocrine tumours metastatic to the liver. Outcomes may be favourable in exquisitely selected patients, yet the optimal selection criteria have not yet been elucidated. Multivisceral transplantation is valid but rarely utilised, for example, in cases of metastatic bulk threatening gut vascular supply.